Exclusive Summary

• - Fully off-patent worldwide; IV NAC is an open generic market well-suited for distribution partnerships into hospital/ED channels.
• - The core indication (acetaminophen/paracetamol overdose) generates hundreds of thousands of ED visits annually across high-income markets, with NAC as first-line, time-critical antidote.
• - Listed on the WHO Essential Medicines List; major guidelines (AASLD/EASL/NICE) recommend NAC as standard care; the 4 g/20 mL strength fits both 21-hour and two-bag regimens.
• - Competition is generic and price-driven but periodic shortages occur; reliable, compliant supply and registration experience can differentiate.
• - Versus originator brands, generics typically deliver 40–70% cost savings; with ~5–6 vials per adult course, budget impact is meaningful.